The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta. Source: BioSpace

The deal is expected to close in the first quarter of 2018. Source: BioSpace

Dr. Hillan will remain on, and Mr. Wise will join, the Company’s Board of Directors. Source: BioSpace

As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting…

Admelog is a rapid-acting insulin similar to Humalog, another insulin lispro 100 Units/mL, currently approved in the U.S. Source: BioSpace

In investment jargon, a "unicorn" has at least two meanings. Source: BioSpace

This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016. Source: BioSpace

The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies. Source: BioSpace

The approval for EGPA is based on results from the pivotal, 52-week, Phase III MIRRA1 study, conducted as a collaboration between GSK and the NIAID, part of the US NIH.…

Teva may be passing out more pink slips as the company looks to cut up to 10,000 jobs in order to save up to $2B in costs over the next…